Cigna’s announcement to shift away from prescription drug rebates for its fully insured plans in 2027 and for Express Scripts’ customers in 2028 is another signal of ongoing change in how pharmacy economics may be structured in the future. The transition from post-sale rebates to up-front discounts has the potential to redefine how value is measured across the drug supply chain but the ultimate impact on payers, members, and overall drug costs remains uncertain. This shift reinforces the need for clear strategies and accountability as stakeholders navigate the evolving marketplace and underscores the urgent need for transparency, innovation, and accountability.
At Expion Health, those principles aren’t new. They’re foundational.
Transparency and Independence at Our Core
From day one, Expion Health was built to challenge the traditional PBM model — a model too often shaped by opaque contracts and conflicting financial incentives. Our commitment to transparency and independence allows us to focus purely on what matters: delivering the lowest net cost and ensuring patients can afford the medications they need.
Staying Ahead of Industry Change
The pharmacy landscape is shifting faster than ever and Cigna’s announcement is just one sign of how rapidly the pharmacy landscape is evolving. At Expion Health, we don’t just respond to change — we anticipate it.
Our team continuously tracks the forces transforming pharmacy economics, from direct-to-consumer strategies and biosimilar expansion to emerging legislative and regulatory shifts. These trends aren’t just headlines to us; they’re signals that shape how we build smarter, more adaptive strategies for our clients.
Through this forward-looking approach, Expion helps payers, plans, and self-insured employers stay ahead of market trends and achieve meaningful, lasting savings. Whether it’s preparing for new reimbursement models, capturing opportunities across multiple cost channels, or aligning with a future that prioritizes transparency and value, we ensure our clients are ready for what’s next, not just what’s now.
ExpionIQ: Powering a Multi-Channel Approach
Our award-winning ExpionIQ platform is uniquely designed to optimize the lowest net cost across all channels. By integrating data, analytics, and actionable insights, ExpionIQ helps clients capture savings from every available opportunity — from manufacturer discount programs to evolving biosimilar strategies and direct-to-consumer pathways. This technology advantage means clients can confidently navigate a market in flux.
The Role and Reassessment of Rebates
Rebates have long played a central role in how plans manage drug costs, but they’ve also added complexity and obscured true pricing transparency. Any move away from rebates, including Cigna’s new approach, must be carefully evaluated to determine whether it delivers genuine value or simply redistributes costs within the system.
At Expion Health, our priority is ensuring that change translates into greater affordability for members and patients, not higher out-of-pocket expenses. Expion’s independence enables us to objectively analyze new pricing and reimbursement models, validate whether they achieve true net savings, and guide our clients with confidence through each stage of this evolving marketplace.
The Bottom Line
Cigna’s move underscores what Expion Health has long known: the future of pharmacy benefits is transparent, data-driven, and patient-centered. With ExpionIQ, our clients are already equipped to thrive in this new reality by leveraging a multi-channel approach to navigate cost-of-goods dynamics, capture real savings, and drive affordability for the members who depend on them.
Want to explore how Expion can help you navigate pharmacy benefit changes and lower costs? Connect with us here.
